Book chapter 575 views
Gene Transfer for Pain: A tool to cope with the intractable, or an unethical endurance-enhancing technology?
The Ethical Challenges of Emerging Medical Technologies, Pages: 395 - 406
Swansea University Author:
Michael McNamee
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.4324/9781003074984-33
Abstract
In this chapter, the authors consider two plausible scenarios in which an individual is seeking treatment with the gene transfer tools to cope better with pain. In the first scenario the individual is a patient; in the second an athlete. The authors employ a comparative strategy to highlight the sim...
Published in: | The Ethical Challenges of Emerging Medical Technologies |
---|---|
ISBN: | 978-100010895-8 9781003074984 |
Published: |
Routledge
2020
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa55754 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract: |
In this chapter, the authors consider two plausible scenarios in which an individual is seeking treatment with the gene transfer tools to cope better with pain. In the first scenario the individual is a patient; in the second an athlete. The authors employ a comparative strategy to highlight the similarities and dissimilarities between the ethical frameworks used to evaluate the two scenarios, and to reach the conclusions regarding the justifiability of the potential practice. The World Anti-Doping Agency sets out three criteria used in the decision to call a product or process ‘doping’. These pertain to the (potential) performance-enhancing effects; the potential harm to the health; the (potential) health risks. In endurance sports, the use of Vascular Endothelial Growth Factor-gene transfer as an endurance enhancement technology is not merely ethically unjustifiable; it compromises an element essential to the activity itself. |
---|---|
Item Description: |
Edited by Arthur L. Caplan, Brendan Parent |
College: |
Faculty of Science and Engineering |
Start Page: |
395 |
End Page: |
406 |